Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $64.53

CRISPR Therapeutics AG (NASDAQ:CRSP) has been assigned an average recommendation of “Hold” from the eighteen research firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $64.5294.

Several equities analysts have issued reports on CRSP shares. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Piper Sandler reiterated an “overweight” rating and set a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a report on Tuesday, March 17th. TD Cowen boosted their price objective on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Citizens Jmp decreased their price objective on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a report on Friday, January 30th. Finally, Citigroup reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, February 16th.

Insider Activity

In related news, General Counsel James R. Kasinger sold 3,182 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $148,853.96. Following the sale, the general counsel directly owned 94,308 shares in the company, valued at $4,411,728.24. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Naimish Patel sold 3,150 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $48.26, for a total transaction of $152,019.00. Following the sale, the insider directly owned 13,143 shares of the company’s stock, valued at $634,281.18. This represents a 19.33% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 141,828 shares of company stock valued at $7,744,397. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors have recently modified their holdings of the company. Mcguire Capital Advisors Inc. acquired a new position in CRISPR Therapeutics in the fourth quarter valued at $25,000. Ramirez Asset Management Inc. acquired a new stake in CRISPR Therapeutics during the 4th quarter worth about $26,000. Optiver Holding B.V. grew its holdings in CRISPR Therapeutics by 71.4% during the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after acquiring an additional 210 shares during the period. Thompson Investment Management Inc. bought a new position in shares of CRISPR Therapeutics in the 3rd quarter worth about $33,000. Finally, Strategic Advocates LLC bought a new position in shares of CRISPR Therapeutics in the 3rd quarter worth about $34,000. 69.20% of the stock is owned by institutional investors.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Zacks highlights why CRISPR “outpaced the stock market” today, calling attention to recent investor interest and momentum that can attract short-term buying. Read More.
• Neutral Sentiment: CRISPR has been a “trending” name on Zacks/Yahoo finance pages — elevated attention can boost volume and volatility but doesn’t by itself change fundamentals. Read More. · Read More.
• Neutral Sentiment: Multiple short-interest reports show reported short interest of zero shares as of March 24 — the figures appear to contain data or reporting anomalies (NaN increases). Practically, reported zero short interest reduces the likelihood of a short-squeeze narrative, but the data should be treated cautiously until clarified by exchanges or data vendors.
• Negative Sentiment: CEO Samarth Kulkarni sold 10,020 shares on March 23 at an average ~$46.78 (≈$468.7K). Insider sales can be interpreted negatively by some investors despite the CEO retaining a substantial stake (255,501 shares). SEC filing: Read More.
• Negative Sentiment: General Counsel James Kasinger sold 3,182 shares on March 23 at the same average price (~$46.78). Additional insider selling amplifies the negative signal for some investors, though both insiders remain significant holders. SEC filing: Read More.

CRISPR Therapeutics Trading Up 1.4%

Shares of CRSP stock opened at $47.09 on Monday. The firm has a market capitalization of $4.52 billion, a price-to-earnings ratio of -7.22 and a beta of 1.72. The business’s 50-day moving average price is $52.70 and its 200-day moving average price is $56.95. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The firm had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. During the same period in the prior year, the company earned ($1.01) EPS. The business’s quarterly revenue was down 97.8% compared to the same quarter last year. On average, sell-side analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.